Hiroaki Ochiiwa

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Chihoko Yoshimura, Hiromi Muraoka, Hiroaki Ochiiwa et al. · Molecular Cancer Therapeutics · 2019 · 65 citations

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <i>In Vivo</i> Antitumor Properties and a Favorable Tolerability Profile

Hidenori Fujita, Kazutaka Miyadera, Masanori Kato et al. · Molecular Cancer Therapeutics · 2013 · 37 citations

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

Hiroaki Ochiiwa, Guzhanuer Ailiken, Masataka Yokoyama et al. · Oncogene · 2021 · 30 citations · Full text

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh et al. · Molecular Cancer Therapeutics · 2013 · 28 citations

Abstract A270, Pathology, Cellular Phosphorylation +16